Equities Analysts Issue Forecasts for CMPS Q1 Earnings

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) – Stock analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of COMPASS Pathways in a research note issued to investors on Tuesday, July 15th. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings of ($0.38) per share for the quarter. HC Wainwright has a “Buy” rating and a $45.00 price target on the stock. The consensus estimate for COMPASS Pathways’ current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for COMPASS Pathways’ Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.41) EPS and Q4 2026 earnings at ($0.43) EPS.

COMPASS Pathways (NASDAQ:CMPS) last posted its earnings results on Thursday, May 8th. The company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.03.

Several other research firms have also recently issued reports on CMPS. Evercore ISI reaffirmed an “in-line” rating and issued a $6.00 price objective (down from $11.00) on shares of COMPASS Pathways in a research report on Monday, June 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $12.00 price objective on shares of COMPASS Pathways in a research report on Tuesday, May 27th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, COMPASS Pathways currently has a consensus rating of “Moderate Buy” and an average price target of $17.00.

COMPASS Pathways Stock Performance

Shares of CMPS opened at $3.93 on Wednesday. The company has a quick ratio of 10.18, a current ratio of 10.18 and a debt-to-equity ratio of 0.11. The business’s 50 day moving average price is $3.94 and its 200-day moving average price is $3.77. COMPASS Pathways has a 52 week low of $2.25 and a 52 week high of $8.54. The stock has a market cap of $367.69 million, a P/E ratio of -1.97 and a beta of 2.12.

Institutional Investors Weigh In On COMPASS Pathways

A number of institutional investors have recently bought and sold shares of the business. Acadian Asset Management LLC boosted its holdings in shares of COMPASS Pathways by 42.0% during the 1st quarter. Acadian Asset Management LLC now owns 240,591 shares of the company’s stock valued at $686,000 after purchasing an additional 71,112 shares during the last quarter. Woodline Partners LP boosted its holdings in shares of COMPASS Pathways by 279.9% during the 1st quarter. Woodline Partners LP now owns 1,754,856 shares of the company’s stock valued at $5,019,000 after purchasing an additional 1,292,927 shares during the last quarter. Polar Asset Management Partners Inc. bought a new position in shares of COMPASS Pathways during the 1st quarter valued at about $657,000. Nantahala Capital Management LLC boosted its holdings in shares of COMPASS Pathways by 182.9% during the 1st quarter. Nantahala Capital Management LLC now owns 2,829,232 shares of the company’s stock valued at $8,092,000 after purchasing an additional 1,829,232 shares during the last quarter. Finally, Royal Bank of Canada boosted its holdings in shares of COMPASS Pathways by 49.8% during the 1st quarter. Royal Bank of Canada now owns 89,446 shares of the company’s stock valued at $256,000 after purchasing an additional 29,733 shares during the last quarter. Hedge funds and other institutional investors own 46.19% of the company’s stock.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.